MORRISTOWN, N.J., Nov. 29, 2012 /PRNewswire/ -- BioNeutral Group, Inc. (OTCBB: BONU) a specialty life science technology based company is proud to announce today that upon the successful completion of a comprehensive executive search program Mr. Ray Dunning and Mr. Kenneth Munson will be joining the company as V.P Medical Sales and V.P. Industrial/Institutional Sales, respectively.
Mr. Dunning has over twenty five years of experience in the Health Care business, thirteen of which at the Steris Corporation, one of the world's leading suppliers of sterilization products. During his last four years at Steris, Ray served as V.P. Sales of its American Health Care Division. Prior to that, he served in sales positions at Roche Diagnostics Systems, NOVA Biomedical Corporation and U.S. Surgical Corporation.
Mr. Munson has over forty years of experience in the specialty chemical business with a focus and expertise in launching innovative technical healthcare products. During this time he has held a number of senior marketing and sales positions with Dubois Chemical Inc, Texo Corporation and the Orchem Corporation. Most recently he functioned as a full time consultant to Suarez Corporation Industries spearheading new product sales and marketing efforts in the disinfectant technology and infection control areas.
BioNeutral's CEO, Mark Lowenthal, stated, "following the successful testing of BioNeutral's Ygiene® product at both the Barnabas Medical Center as a pre-soak disinfectant and at a leading independent statistical institute where it's anti anthrax capabilities proved outstanding, the product was now ready for broad scale commercialization for which both Ray and Ken are uniquely qualified to lead. This process will begin immediately."
About BioNeutral Group, Inc.
Headquartered in Morristown, New Jersey with lab facilities at the New Jersey Institute of Technology in Newark, BioNeutral Group, Inc., is a specialty technology-based life-science company that has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene® and Ogiene®, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene® brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also permitted to be sold in the UK, France and Sweden. Auto Neutral is a registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutral.com.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
Forward-Looking Statements: This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene-206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and are available for sale in the United States.
SOURCE BioNeutral Group, Inc.